Responses
Poster sessions
Idiopathic pulmonary fibrosis boldly goes where no disease has gone before
P9 Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis – initial clinical experience in a UK cohort
Compose a Response to This Article
Other responses
No responses have been published for this article.